Why Dyne Therapeutics Stock Crushed the Market on Monday

That peer is Avidity Biosciences, which has agreed to be purchased by pharmaceutical giant Novartis in a deal that values the company at $12 billion. Novartis is paying a premium of 42% for Avidity’s …